Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Ichthammol→

Ichthammol PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
8029-68-3
Molecular formula
Not available
Molecular weight
76.055 g/mol
Drug class
Sulfonated shale-oil derivativetopical anti-inflammatory and antiseptic ingredient
Mechanism of action
A complex sulfonated shale-oil preparation with reported local anti-inflammatory, antimicrobial and antipruritic effects. Proposed anti-inflammatory actions include inhibition of lipoxygenase and cyclooxygenase pathways; the composition is a mixture rather than a single molecular drug.
Indications / reported uses
  • Topical use in selected inflammatory skin preparations and drawing-salve products; specific indications depend on the registered formulation. Some US OTC ichthammol labels are marketed as unapproved homeopathic products and should not be treated as evidence of established efficacy.

Sources: https://www.ichthyol.de/en/raw-materials-for-corporate-customers/ichthammol/ · https://www.ndf.gov.sg/about-drugs/active-ingredient/m00462/ · https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bdbeeb95-5c46-9a24-e053-2a95a90aa397

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Sulfonated shale-oil derivative; topical anti-inflammatory and antiseptic ingredient

Mechanism of action

A complex sulfonated shale-oil preparation with reported local anti-inflammatory, antimicrobial and antipruritic effects. Proposed anti-inflammatory actions include inhibition of lipoxygenase and cyclooxygenase pathways; the composition is a mixture rather than a single molecular drug.

General use cases

  • Topical use in selected inflammatory skin preparations and drawing-salve products; specific indications depend on the registered formulation. Some US OTC ichthammol labels are marketed as unapproved homeopathic products and should not be treated as evidence of established efficacy.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Ichthammol PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Ichthammol Permitted Daily Exposure (PDE) report (the Ichthammol PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Ichthammol Occupational Exposure Limit (OEL) report (the Ichthammol OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.